



Cornerstone Pharmaceuticals, Inc  
1 Duncan Drive  
Cranbury, NJ 08512

Media Contact: Meghan Weber  
Liza Sullivan & Associates  
(917) 399-8713

## **Cornerstone Pharmaceuticals Awarded \$490K in Grants Under QTDP Program**

**Cranbury, NJ, November 5, 2010** – Cornerstone Pharmaceuticals, Inc., a leader in cancer metabolism-based therapeutics, today announced that it has been awarded \$489,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program. As part of the Patient Protection and Affordable Care Act of 2010, the QTDP program provides a tax credit to encourage investments in new therapies to prevent, diagnose and treat acute and chronic diseases.

Proceeds of the grant to Cornerstone will be used to advance the development of the company's lead Altered Energy Metabolism Directed (AEMD) platform drug, CPI-613, and EmPAC, the company's lead Emulsiphan drug delivery product candidate.

"The QTDP grant speaks to the strength of Cornerstone's current drug and drug delivery programs," said Dr. Robert Shorr, CEO of Cornerstone Pharmaceuticals, Inc. "The funding will be used to advance our clinical and non-clinical programs intended to result in new, better performing drugs for patients suffering from a variety of different cancer types."

Cornerstone's lead drug candidate from its AEMD platform, CPI-613, is a first-in-class, small molecule drug. It is currently being evaluated in three Phase I, I/II clinical trials. EmPAC, the company's lead Emulsiphan drug delivery technology product candidate, is in preclinical testing.

### **About Cornerstone Pharmaceuticals**

Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. Cornerstone currently has a drug in clinical trials targeting certain key enzymes crucial to cancer cell metabolism. AEMD compounds, the company's unique approach to cancer treatment, is the leading platform in cancer metabolism. It has facilitated the discovery of first-in-class drugs as well as a novel drug delivery technology - both with the potential to transform the way cancer is treated. For further information, visit [www.cornerstonepharma.com](http://www.cornerstonepharma.com).

### **About AEMD/CPI-613**

CPI-613 is the first drug in a new chemical class that, through a novel mechanism, targets metabolic changes considered to be common to many, if not all, cancer types and minimally functional in normal cells.



CPI-613 is the lead drug from Cornerstone's Altered Energy Metabolism Directed (AEMD) platform. Patients with solid tumors and hematologic cancers are currently being enrolled in multiple Phase I and Phase I/II human clinical trials evaluating CPI-613. These trials include a Phase I/II single agent trial for patients with solid tumors who have been failed by other therapy options, a Phase I/II combination trial with gemcitabine in newly diagnosed or relapsed patients, and a single agent trial in hematologic malignancies. CPI-613 was granted orphan drug status by the US FDA for pancreatic cancer, which has a poor prognosis, spreads rapidly and often goes undetected in its early stages.

### **About Emulsiphan/EmPAC**

Emulsiphan is a novel drug-delivery technology that deposits cancer-fighting drugs directly into cancer cells--not just the tumor mass--by focusing on the distinct metabolism of these cells. Just as the body needs nutrients to survive, cancer cells depend on certain nutrients to make energy and to proliferate. Emulsiphan contains nutrients that are attractive to tumors and therefore taken up by them. Cornerstone's lead Emulsiphan product candidate is EmPAC, a reformulated paclitaxel product that has demonstrated increased safety and efficacy versus paclitaxel alone in preclinical testing.

### **About Cancer Metabolism**

Cancer cell metabolism is an exciting and promising area for the development of drugs to treat cancer. While it has been known for nearly a century that cancer cells have a unique metabolism, only recently has there been a broad and significant renewal of scientific interest focused on exploring this unique metabolic difference to facilitate the discovery and development of groundbreaking therapies. Unlike normal cell metabolism, cancer cell metabolism utilizes less oxygen and has different nutritional requirements to survive and proliferate. This metabolic difference is considered to be fundamental to the transformation of normal cells into cancer cells and is believed to be conserved in all cancers, including solid tumors, lymphoma and leukemia. By better understanding these cancer-specific metabolic processes, researchers in the field hope to find new drugs to revolutionize cancer treatment.

# # #

This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.